Leaders in areas such as drug discovery, clinical development and market access will meet to discuss AI, failing life expectancy, and a new generation of talent.
On May 16, the Financial Times US Pharma and Biotech Summit will take place in New York. With more than 40 speakers expected to participate and representation from over 255 companies, the summit will focus on discussions around the following:
Christopher Viehbacher, president, CEO for Biogen, will begin the conference with a keynote interview. Some of the sessions throughout the day will include:
Speakers at the event include Robert Truckenmiller, SVP, Head of US Vaccines, GSK; Linda Fried, Dean and DeLamar Professor of Public Health, Columbia University; Amy West, head of US Digital Transformation and Innovation, Novo Nordisk, and many more.
As part of the MJH Life Sciences community, you can save 20% off on your in-person and digital pass with discount code MJH: https://bit.ly/3U6N7p7
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.